It is likely that the risk of cardiovascular events from pharmaceuticals as COX-2 inhibitors can be reduced significantly by standard pharmaceutical and lifestyle preventative measures-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

It is likely that the risk of cardiovascular events from pharmaceuticals as COX-2 inhibitors can be reduced significantly by standard pharmaceutical and lifestyle preventative measures

Published:2006-01 Issue:6 Volume:67 Page:1333-1337
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Hellstrom H.R.

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Cyclooxygenase inhibition and cardiovascular risk;Antman;Circulation,2005

2. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis;Hippisley-Cox;BMJ,2005

3. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events;Chan;Circulation,2006

4. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension;Bulut;J Hypertens,2003

5. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study;Graham;Lancet,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. More evidence standard preventative measures can prevent COX-2 inhibitor-induced infarctions;Medical Hypotheses;2008-11

2. A proposed fairer method for conducting rofecoxib trials;Medical Hypotheses;2007-01

3. A pathogenetic mechanism for COX-2 inhibitor-induced cardiovascular events proposed to be useful in structuring medical testimony in rofecoxib trials;Medical Hypotheses;2007-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3